% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Habl:126644,
author = {G. Habl and S. Katayama and M. Uhl and K. A. Kessel and L.
Edler$^*$ and J. Debus$^*$ and K. Herfarth and F.
Sterzing$^*$},
title = {{H}elical intensity-modulated radiotherapy of the pelvic
lymph nodes with a simultaneous integrated boost to the
prostate--first results of the {PLATIN} 1 trial.},
journal = {BMC cancer},
volume = {15},
number = {1},
issn = {1471-2407},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2017-02672},
pages = {868},
year = {2015},
abstract = {Definitive, percutaneous irradiation of the prostate and
the pelvic lymph nodes in high-risk prostate cancer is the
alternative to prostatectomy plus lymphadenectomy. To date,
the role of whole pelvis radiotherapy (WPRT) has not been
clarified especially taking into consideration the benefits
of high conformal IMRT (intensity modulated radiotherapy) of
complex-shaped target volumes.From 2009 to 2012, 40 patients
of high-risk prostate cancer with an increased risk of
microscopic lymph node involvement were enrolled into this
prospective phase II trial. Patients received at least two
months of antihormonal treatment (AT) before radiotherapy
continuing for at least 2 years. Helical IMRT (tomotherapy)
of the pelvic lymph nodes (51.0 Gy) with a simultaneous
integrated, moderate hypofractionated boost (single dose of
2.25 Gy) to the prostate (76.5 Gy) was performed in 34
fractions. PSA levels, prostate-related symptoms and quality
of life were assessed at regular intervals for 24 months.Of
the 40 patients enrolled, 38 finished the treatment as
planned. Overall acute toxicity rates were low and no acute
grade 3 or 4 gastrointestinal (GI) and genitourinary (GU)
toxicity occurred. $21.6\%$ of patients experienced acute
grade 2 but no late grade ≥ 2 GI toxicity. Regarding GU
side effects, results showed $48.6\%$ acute grade 2 and
$6.4\%$ late grade 2 toxicity. After a median observation
time of 23.4 months the PLATIN 1 trial can be considered as
sufficiently safe meeting the prospectively defined aims of
the trial. With 34/37 patients free of a PSA recurrence it
shows promising efficacy.Tomotherapy of the pelvic lymph
nodes with a simultaneous integrated boost to the prostate
can be performed safely and without excessive toxicity. The
combined irradiation of both prostate and pelvic lymph nodes
seems to be as well tolerated as the irradiation of the
prostate alone.Trial Numbers: ARO 2009-05,
ClinicalTrials.gov: NCT01903408.},
cin = {C060 / E050},
ddc = {610},
cid = {I:(DE-He78)C060-20160331 / I:(DE-He78)E050-20160331},
pnm = {315 - Imaging and radiooncology (POF3-315)},
pid = {G:(DE-HGF)POF3-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26547188},
pmc = {pmc:PMC4637144},
doi = {10.1186/s12885-015-1886-5},
url = {https://inrepo02.dkfz.de/record/126644},
}